Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

7,308 total articles

Huntington Bancshares: Watching a Risk-Reward Setup Around $15.45

Huntington Bancshares: Watching a Risk-Reward Setup Around $15.45

Huntington (HBAN) trades near $15.45, a valuation that looks inexpensive relative to growth and free cash flow, while near-term catalysts (merger synergies, sector momentum, and dividend yield) could re-rate the stock. The trade below is a mid-term swing (45 trading days) long with a clear stop and target. This is not a blind buy — credit trends an…

Buy 10x Genomics on a Consumables Re-rate: Cheap FCF with Upside to $30

Buy 10x Genomics on a Consumables Re-rate: Cheap FCF with Upside to $30

10x Genomics (TXG) is an actionable long: the stock trades at a $2.45B market cap, is generating meaningful free cash flow ($130.1M trailing), and is moving toward a higher-margin, consumables-led revenue mix that should compress multiples and re-rate the shares. Technicals are neutral and short interest remains material, so use a defined entry and…

MDA Space: From Momentum to Metrics - Downgrading to a Tactical Short

MDA Space: From Momentum to Metrics - Downgrading to a Tactical Short

MDA Space ($32.56) trades like a high-growth story but now carries stretched multiples (P/E 50.2, P/B 4.0) and declining technicals. With price well below short-term moving averages, heavy short interest on recent volume spikes, and upcoming execution-dependent milestones across Robotics and Satellite Systems, the easy upside is largely priced in. …

Greg Abel's First Moves: An Actionable Trade on Berkshire Hathaway

Greg Abel's First Moves: An Actionable Trade on Berkshire Hathaway

Greg Abel's early actions as CEO - a personal $15M buy and the restart of repurchases - create an actionable long trade on Berkshire Hathaway. Valuation looks reasonable (P/E ~15, P/B ~1.44) while FCF and a $1.04T market cap anchor upside. This trade targets a rebound toward the upper half of the 52-week range over a 180-trading-day horizon, with a…

Micron's AI Memory Boom: Buy the Dip While Supply Still Controls the Cycle

Micron's AI Memory Boom: Buy the Dip While Supply Still Controls the Cycle

Micron is trading well below its recent highs after a market pullback, but underlying fundamentals - low leverage, double-digit free cash flow, and sold-out HBM capacity - look very similar to the early stages of Nvidia's profit re-rating. This is a tradeable long: enter at $405.00, stop at $360.00, target $550.00 over a long-term, 180 trading day …

TRIN: High-Yield BDC With Income Support and Reprice Potential

TRIN: High-Yield BDC With Income Support and Reprice Potential

Trinity Capital (TRIN) offers a compelling income entry today: a monthly $0.17 dividend (14%+ yield) backed by a growing investment book, modest valuation (P/B ~1.07, P/E ~7.3) and a market cap around $1.2B. The trade targets mean reversion toward recent highs while collecting outsized cash distribution; downside is controlled with a sub-$13 stop i…

Apogee Therapeutics: Betting on Twice-Yearly Dosing to Reprice a Biotech

Apogee Therapeutics: Betting on Twice-Yearly Dosing to Reprice a Biotech

Apogee Therapeutics (APGE) is a clinical-stage biotech that just put itself squarely in the market's spotlight: compelling 16-week Phase 2 data, a long half-life TSLP program enabling infrequent dosing, and a 52-week APEX readout on 03/23/2026. This trade idea lays out a defined long with entry, stop and target for a long-term swing (180 trading da…

Lyell Immunopharma: Promising CAR-T Data, Time to Trade More Precisely

Lyell Immunopharma: Promising CAR-T Data, Time to Trade More Precisely

Lyell's dual-targeting CAR-T (ronde-cel / LYL314) has delivered impressive early response data and the company just closed a $50M tranche that extends runway into Q2 2027. The story remains fundamentally attractive, but the path to commercialization and financing risk keep this a high-volatility trade. We outline a tactical long with strict stops a…

Why SoFi Could Snap Back From a Brutal Reset: A Measured Long Trade

Why SoFi Could Snap Back From a Brutal Reset: A Measured Long Trade

SoFi (SOFI) has been punished recently by a secondary offering, a high-profile short report and crypto-related headline risk. The business, however, still posted $3.61B in 2025 revenue (+35% YoY), 13.7M members (+35%) and reported GAAP profitability across recent quarters. With a market cap near $21.9B, conservative leverage and insider buying, the…

Cloudflare: I Bought at $170 — My Next Add Is at $210 (Target $260)

Cloudflare: I Bought at $170 — My Next Add Is at $210 (Target $260)

Cloudflare is expensive on headline multiples, but its role as global edge infrastructure and recent momentum make a tactical add attractive. I personally loaded at $170 and plan to add if shares pull back to $210, with a stop at $195 and a primary target near the 52-week high at $260. The trade is driven by accelerating enterprise deal flow, impro…

NVDA: Market Pessimism Looks Overdone - A Mid‑Term Long Trade

NVDA: Market Pessimism Looks Overdone - A Mid‑Term Long Trade

Nvidia remains the engine of the AI data-center cycle: $4.33T market cap, exceptional ROE and free cash flow, and low leverage. Near-term selling has pushed momentum indicators into neutral-to-bearish territory, but fundamentals and catalysts (AI demand, new energy partnerships, industry spend signals) argue for a mid-term rebound. I outline a clea…

Buy the Discount, But Watch the Balance Sheet: XPLR Infrastructure as a Levered Play on the Energy Transition

Buy the Discount, But Watch the Balance Sheet: XPLR Infrastructure as a Levered Play on the Energy Transition

XPLR Infrastructure (XIFR) is trading at a steep price-to-book discount (P/B ~0.29) despite owning contracted battery, solar, and wind cash flows. The equity looks actionable as a long-term trade around $10.10, but heavy leverage (debt-to-equity ~1.98), negative free cash flow, and active securities litigation mean this is a conditional opportunity…